Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Investors

Analyst Coverage
Degroof Petercam

Laura Roba


Edison Investment Research

Pooya Hemami


H.C. Wainwright

Yi Chen


KBC Securities

Jacob Mekhael


Van Lanschot Kempen

Luisa Morgado

Edison Research

Click here to receive Edison’s research on Sequana Medical in real-time

Any opinions, estimates or forecasts regarding Sequana Medical’s performance made by these analysts are those of the author and do not reflect the views of Sequana Medical and its management. Sequana Medical does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. To obtain a copy of their research reports, please contact their respective institutions.

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES